Sanofi strengthens its leadership in the treatment of hemophilia

Sanofi presented new data on its ALTUVIIIO and fitusiran treatments at the 32nd Congress of the International Society of Thrombosis and Hemostasis (ISTH) in Bangkok. These presentations reaffirm Sanofi's position in the field of hemophilia.

Interim results from the Phase III XTEND-ed study show that weekly administration of ALTUVIIIO continues to provide effective protection against bleeding in patients with severe hemophilia A. Oral communications at the congress also revealed that fitusiran has strong prophylactic potential for hemophilia A or B.

The U.S. Food and Drug Administration (FDA) has accepted the application for review of fitusiran, with a decision expected by March 28, 2025. These advances could diversify the treatment options available to patients.